The Compound Report is an educational resource. Nothing on this site constitutes medical advice or encourages personal use of any compound. Always consult a qualified healthcare provider.
Educational reference only. Nothing on this page constitutes medical advice or encourages personal use of this compound. Always consult a qualified healthcare provider before any decision involving your health.
When the community says ‘TB-500,’ they mean LKKTETQ. When clinical trials test ‘Thymosin Beta-4,’ they mean the full 43-AA protein. These are not the same compound. This chapter documents the fragment.
The terminology emerged historically: Thymosin Beta-4 was studied as a healing peptide beginning in the 1990s. Research peptide vendors synthesized fragments of Tβ4 because synthesizing the full 43-AA protein is more expensive and technically demanding than synthesizing a 7-AA fragment. LKKTETQ (Fragment 17-23, the actin-binding domain) became the standard 'TB-500' product because it is the most commercially accessible and most widely referenced as the 'active' domain. The academic and clinical trial literature predominantly uses full-length recombinant Thymosin Beta-4 (Thymosin β4). The community uses LKKTETQ. Evidence generated from full Tβ4 trials is not directly transferable to LKKTETQ without validation studies comparing the two — which have not been conducted.
THE CENTRAL TENSION
TB-500 (LKKTETQ) is the community's most widely used healing peptide stack component. It appears in the Wolverine Stack, the GLOW Stack, and is sold by virtually every major peptide vendor. The pharmacological rationale (actin-binding domain drives cell migration; cell migration enables healing) is coherent. The full Thymosin Beta-4 protein has clinical trial evidence including a Phase 2b cardiac trial (NCT05984134). LKKTETQ itself has zero human clinical trials. The community is using a 7-AA fragment assuming it recapitulates the pharmacology of a 43-AA protein, when: (1) no comparative pharmacokinetic study of fragment vs full protein has been published; (2) full Tβ4 has additional receptor interactions and signaling pathways beyond actin sequestration that LKKTETQ does not cover; (3) every human safety and efficacy data point is from the full protein. LKKTETQ may work exactly as community users expect — the actin-binding domain is the primary mechanism, and the fragment approach is pharmacologically reasonable. Whether it works as well as the full protein is unknown.
The community product sold as 'TB-500' is LKKTETQ, a 7-AA fragment. Clinical trials use full 43-AA recombinant Thymosin Beta-4. They share the actin-binding mechanism but the full protein has additional signaling mechanisms. Evidence from full Tβ4 trials (NCT05984134 cardiac; wound healing) does not directly validate the LKKTETQ fragment. Whether LKKTETQ produces equivalent healing outcomes to full Tβ4 has never been tested in a comparative trial.
NCT05984134 used full recombinant Tβ4 protein by IV/SC injection in acute MI patients. Community users inject LKKTETQ subcutaneously for musculoskeletal healing. Different compound, different dose, different route context, different indication. The Phase 2b cardiac results (when published) provide evidence for the full protein in cardiac repair, not for the fragment in musculoskeletal use. The pharmacological logic connecting them is coherent but the evidence does not directly transfer.
Actin exists in cells in two forms: G-actin (globular, monomeric, the 'building block') and F-actin (filamentous, polymerized, the 'structure'). Cell migration requires dynamic regulation between these two forms — when a cell moves, it extends lamellipodia and filopodia by rapidly polymerizing G-actin into F-actin at the leading edge while depolymerizing F-actin at the trailing edge. Thymosin Beta-4 (and by inference LKKTETQ) binds G-actin and sequesters it as a free pool available for rapid polymerization on demand. This sequestration: (1) prevents unwanted random F-actin polymerization; (2) maintains a large available pool of G-actin ready for directed polymerization; (3) allows rapid cell shape changes and directed migration when signaled. The net effect is enhanced capacity for cell migration in response to repair-directing signals.
In tissue repair, multiple cell types must migrate to the injury site: endothelial cells (for angiogenesis — new vessel growth); smooth muscle cells (for vessel stabilization); fibroblasts (for ECM deposition); stem and progenitor cells (for tissue regeneration). All of these migrations depend on actin dynamics. LKKTETQ, by regulating the G-actin pool, facilitates the migration capacity of all these repair-competent cells simultaneously. This is the mechanistic basis for Thymosin Beta-4/TB-500's described 'systemic healing' effect — it enhances the migratory capacity of repair cells throughout the body. Smart et al. (2007, Nature) showed Thymosin Beta-4 activates epicardial progenitor cell mobilization — the same progenitor cell trafficking mechanism that TB-500 is credited with in the Wolverine and GLOW stacks.
Beyond actin sequestration, full Thymosin Beta-4 (43 AA) signals through ILK (integrin-linked kinase) for cell survival and anti-apoptotic signaling; activates PI3K/Akt pathway; stimulates VEGF expression and angiogenesis; modulates inflammatory gene expression through NF-kB pathway; and interacts with pinacidil-sensitive K+ channels in cardiac tissue. These are additional mechanisms of the full protein that the LKKTETQ fragment may not recapitulate — or may recapitulate partially, since ILK binding involves a C-terminal region distinct from the LKKTETQ actin-binding domain. The full pharmacological comparison between LKKTETQ and full Tβ4 has not been conducted.
Evidence Layer
Full Thymosin Beta-4 (Tβ4)
LKKTETQ (Fragment 17-23)
Human clinical trials
Phase 2b cardiac trial (NCT05984134; n=90; acute MI; recombinant Tβ4); Phase 2 wound healing; Phase 1 safety in healthy volunteers (IV)
Zero human clinical trials specifically for LKKTETQ
Animal healing models
Extensive: cardiac repair, tendon healing, wound healing, neural, corneal, bone; multiple labs; multiple species
Animal healing models for TB-500 as sold (LKKTETQ) not consistently distinguished from full Tβ4 in community literature; may share mechanism
Actin-binding characterization
LKKTETQ identified as actin-binding domain via structure-activity studies of full Tβ4
Direct actin-binding confirmed for LKKTETQ sequence
ILK/PI3K/Akt signaling
Confirmed for full Tβ4
Not independently confirmed for LKKTETQ alone
Cardiac progenitor cell mobilization
Smart 2007 (Nature; epicardial progenitor mobilization; full Tβ4)
Not independently demonstrated for LKKTETQ; assumed from mechanism
Community evidence
Extensive (but is actually for LKKTETQ, which is what has been purchased as 'TB-500')
Grade E; consistent healing reports; the real-world community experience with TB-500 products
Fragment 17-23 (LKKTETQ) community protocol is covered in detail in the Wolverine Stack chapter (pbwolverinev4) and the GLOW Stack chapter (pbglowv4), where it functions as the 'TB-500' component. In brief: loading dose 5-10 mg/week (2 injections, e.g. Monday/Thursday) for 4 weeks; maintenance 2-5 mg/week ongoing; SubQ anywhere (systemic mechanism; injection site not relevant to efficacy); 4-8 week cycles with 4 week rest. Polaris and Limitless both carry it, typically as 5mg vials. The key practical point: because LKKTETQ is the systemic cell mobilizer, injection site is irrelevant — injecting near the injury is not beneficial.
Smart N, Risebro CA, Melville AAD, et al. (2007). Thymosin beta4 induces adult epicardial progenitor mobilization and neovascularization. Nature. 445:177-182. [Landmark Nature paper; full Tβ4; epicardial progenitor cell mobilization; cardiac repair; the foundational paper for Tβ4 healing mechanism.]
NCT05984134. Phase 2b trial of recombinant Thymosin Beta-4 (full protein) in acute myocardial infarction. [n=90; placebo vs Tβ4; primary cardiac repair endpoint; enrollment complete as of 2024; results pending; uses FULL PROTEIN, not LKKTETQ fragment.]
Malinda KM, Goldstein AL, Kleinman HK. (1997). Thymosin beta 4 stimulates directional migration of human umbilical vein endothelial cells. FASEB Journal. 11(6):474-481. [Actin-sequestering mechanism; endothelial migration; foundational mechanism paper; full Tβ4.]
Hannappel E. (2010). β-Thymosins, small acidic peptides with multiple functions. Ann N Y Acad Sci. 1194:9-17. [Thymosin beta family structure-activity; LKKTETQ identification as actin-binding domain; comprehensive structure-function review.]
LKKTETQ (what the community calls TB-500) is the actin-binding domain of Thymosin Beta-4 — the mechanism that drives cell migration and systemic healing response. It has extensive community use, coherent pharmacological rationale, and zero human clinical trials for this specific fragment.
— End of TB-500 Fragment 17-23 (LKKTETQ) —
THE PEPTIDE BIBLE | TB-500 Fragment 17-23 (LKKTETQ) | For Research & Educational Purposes Only
TB-500 Fragment 17-23 (LKKTETQ): Leu-Lys-Lys-Thr-Glu-Thr-Gln; heptapeptide; CAS 885340-08-9; MW ~799 Da. Actin-binding domain of Thymosin Beta-4 (positions 17-23 of 43-AA Tβ4). THIS IS WHAT THE COMMUNITY CALLS 'TB-500.' NAMING: every vendor's 'TB-500' = LKKTETQ fragment, NOT full 43-AA Tβ4. Clinical trials (NCT05984134 Phase 2b cardiac; wound healing) use FULL recombinant Tβ4, not LKKTETQ. MECHANISM: G-actin sequestration → maintains free G-actin pool for directed polymerization → enhanced cell migration capacity (endothelial, smooth muscle, progenitor, fibroblast) → systemic repair-competent cell recruitment. ACTIN BINDING: LKKTETQ identified as minimum actin-binding domain of Tβ4 via structure-activity studies (Hannappel 2010). WHAT FULL Tβ4 ADDS BEYOND LKKTETQ: ILK signaling, PI3K/Akt, VEGF upregulation, NF-kB modulation, cardiac K+ channel interaction; these additional pathways not independently confirmed for LKKTETQ alone. EVIDENCE: Smart 2007 (Nature; full Tβ4; epicardial progenitor mobilization). Multiple full Tβ4 animal healing models (cardiac, tendon, wound, neural, corneal). NCT05984134 (Phase 2b; full Tβ4; MI; results pending). LKKTETQ specifically: Grade E (community); Grade C (animal via full Tβ4 extrapolation); ZERO human trials for LKKTETQ fragment. PROTOCOL: loading 5-10 mg/week × 4 weeks (2 injections/week); maintenance 2-5 mg/week; SubQ anywhere (systemic mechanism; injection site irrelevant); 4-8 week cycles; see Wolverine Stack and GLOW Stack chapters for full context. POLARIS and LIMITLESS carry it (5mg vials). COMPANION: pb003tb500v4 (full TB-500 chapter); TB-500 Fragment 1-4 (Ac-SDKP) chapter.
A Structural Modification of Semax With No Published Studies of Its Own. Being Sold as 'The Most Potent Semax Analog.' Every Claim Belongs to Its Parent Compound.
The Compound That Raises NAD+ By Stopping the Body From Destroying It. NNMT: The Enzyme That Wastes Nicotinamide. Fat Loss Without Food Restriction in Mice. The Neelakantan Group's Research Tool Repurposed as a Longevity Drug. Zero Human Trials. 100 mg/Day Community Dose Extrapolated From Mouse IP Injections. The 1-MNA Question: The Metabolite You're Blocking Has Protective Roles in Liver and Kidney. A 2025 Cell/TPS Review Calls for Clinical Translation. Clinics Already Prescribing It Without FDA Ruling on Safety.
Six Human Clinical Trials. 900+ Participants. Safety Indistinguishable From Placebo. Primary Fat Loss Endpoint Failed. WADA Banned. FDA Rejected for Compounding. The Community Uses It Anyway at Doses That Never Worked in the Trials.